
- 1 Unveiling the threat: Characterization of *Clostridioides difficile* Infection in the
- 2 Northwest Region of Buenos Aires between 2019-2023 and Associated Risk
- 3 Factors redefined through a Meta-Analysis
- 4 Angela María Barbero^{1,2,#}, Nicolás Diego Moriconi^{1,#}, Sabina Palma^{1,2,#}, Josefina
- 5 Celano¹, María Gracia Balbi³, Lorenzo Sebastián Morro¹, María Martina Calvo
- 6 Zarlenga⁴, Jorgelina Suárez^{3,5}, María Guadalupe Martínez³, Mónica Graciela
- 7 Machain³, Carlos Gabriel Altamiranda⁴, Gabriel Erbiti^{4,5}, Rodrigo Emanuel
- 8 Hernández Del Pino^{1,2, \(\zeta\)}, Virginia Pasquinelli^{1,2, \(\delta\)}, \(\zeta\).
- 9 1 Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional del
- Noroeste de la Provincia de Buenos Aires (UNNOBA). B6000DNE, Buenos Aires,
- 11 Argentina.
- 2 Centro de Investigaciones y Transferencias del Noroeste de la Provincia de
- Buenos Aires (CIT NOBA), UNNOBA-Universidad Nacional de San Antonio de
- 14 Areco (UNSAdA)-Consejo Nacional de Investigaciones Científicas y Técnicas
- 15 (CONICET). Buenos Aires, Argentina.
- 3 Servicio de Laboratorio, Sala de Microbiología, Hospital Interzonal General de
- 17 Agudos (HIGA) Dr. Abraham F. Piñeyro, Junín, Buenos Aires, Argentina
- 4 Clínica Centro Médico Privado SRL, Junín, Buenos Aires, Argentina
- 5 Universidad Nacional del Noroeste de la Provincia de Buenos Aires (UNNOBA).
- 20 B6000DNE, Buenos Aires, Argentina.
- [#] Angela María Barbero, Nicolás Diego Moriconi and Sabina Palma share first
- 22 authorship.
- ²³ Rodrigo Emanuel Hernández Del Pino Rodrigo and Virginia Pasquinelli share the
- 24 last authorship.
- *Corresponding author: virpasquinelli@gmail.com, Tel: +5492364582417, Address:
- Coronel Borges 379, Junín (Postal Code 6000), Buenos Aires, Argentina.
- 27 **Conflict of interest.** The authors declare that the research was conducted in the
- 28 absence of any commercial or financial relationships that could be construed as a
- 29 potential conflict of interest.
- 1 in 5 diarrheas is caused by C. difficile in the Northwest region of Buenos Aires,
- Argentina. More than the 65% of the cases were community-acquired and involved
- toxigenic strains. Comparison through meta-analysis identified known and also new
- 33 risk factors.

34 **Abstract**

35 Clostridioides difficile stands as the leading cause of hospital acquired enteric infection in developed countries. In Argentina, the epidemiology of *Clostridioides* 36 difficile infection (CDI) is currently poorly characterized. Therefore, we conducted a 37 retrospective case-control study evaluating the prevalence of CDI in 249 stool 38 samples collected between 2019 and 2023 in the Northwest region of Buenos Aires. 39 The presence of *C. difficile* was detected by combining three techniques (EIA, PCR 40 and toxigenic culture) in a diagnostic algorithm. Clinical and demographic data from 41 patients was also analyzed to identify CDI-associated risk factors. 1 in 5 patients 42 43 presented C. difficile as the etiological agent of diarrhea and the 80% of CDI+ cases carried toxigenic strains, most of which had been acquired in the community. Age 44 ≥69 years, previous use of antibiotics, previous hospitalization and previous 45 episodes of CDI emerged as predisposing factors for CDI in our study cohort. Blood 46 47 parameters such as an elevated number of leukocytes and platelets, a decreased basophil count, and an increased urea concentration were identified as indicators of 48 49 CDI. We also carried out a systematic review and a meta-analysis where we contrasted our results with 39 studies selected from different countries around the 50 world. At the global level, the meta-analysis highlighted advanced age, previous 51 52 consumption of antibiotics and previous hospitalization as CDI risk factors and the 53 leukocyte count as an indicator of CDI. These results emphasize the importance of epidemiological studies and reveal crucial information for healthcare decision-54 making regarding CDI. 55

- Keywords: C. difficile, epidemiology, risk factors, meta-analysis
- 57 Running title: Risk factors and meta-analysis of CDI



Introduction

Clostridioides difficile infection (CDI) is considered as the most frequent hospital-acquired disease 1,2. Since 2019, the Centers for Disease Control (CDC) have identified C. difficile as an "urgent threat", with the immediate need to implement prevention and control actions 3. C. difficile is a Gram positive, anaerobic and spore-forming bacterium that causes intestinal damage primarily through the production of two main toxins: toxin A (TcdA) and toxin B (TcdB) 4. These toxins play a crucial role in the pathogenesis of CDI by damaging the cells lining the gut. CDI can be life-threatening, ranging from mild diarrhea to pseudomembranous colitis and causing nearly 500,000 cases per year in the United States 5.

CDI is also a major economic burden to the health care systems, which is closely linked to the high recurrence rates of this infection. Although standard treatments resolve CDI in most cases, up to 35% of CDI-treated patients will experiment a recurrence of the disease with aggravated symptoms ⁵. Common therapy for CDI includes antibiotics such as metronidazole for mild cases and vancomycin or fidaxomicin for moderate to severe cases ⁶. Therapies with the human antibody bezlotoxumab against C. difficile toxin B or Fecal Microbiota Transplant (FMT) to restore the balance of the microbiome have been recommended to treat or prevent recurrences ^{7,8}.

Regarding global epidemiology, while healthcare-associated CDI has declined in recent years, the incidence of community-acquired CDI is on the rise ^{9–14}. The main transmission route for *C. difficile* is through direct Person-to-Person contact by the fecal-oral route ¹⁵. *C. difficile* spores constitute the main form of resistance and can persist in the environment for long periods ^{16,17}. Then, contaminated surfaces, food or water, as well as asymptomatic carriers, are typical sources of community transmission ^{18–20}.

Several risk factors are associated with the development of CDI. The use of antimicrobials with emphasis on broad-spectrum antibiotics, has been described as the most significant risk factor for CDI ^{21,22}. These antibiotics can disrupt the normal balance of bacteria in the gastrointestinal tract, generating dysbiosis and so allowing *C. difficile* overgrow in the gut. Hospitalization in healthcare facilities and advanced age, which can be related to weakened immune systems and a higher likelihood of residing in healthcare settings, also constitute important risk factors ²². The use of stomach acid regulators, such as proton pump inhibitors (PPIs) and H2 blockers, has been associated with an increased risk of CDI ²³; however, this is still under debate. Previous episodes of CDI increase the risk of recurrence ²⁴. Finally, several underlying health conditions that could compromise the immune system could contribute to increased susceptibility or severity of the infection. Comorbidities such as Inflammatory Bowel Disease (IBD) ²⁵, Crohn's disease ²⁵, ulcerative colitis ²⁵, diabetes ²⁶ and chronic kidney disease (CKD) ²⁷ can enhance the risk of CDI.

Certain clinical procedures (e.g. chemotherapy treatments and gastrointestinal surgery), malnutrition or enteral nutrition, organ transplantation along with immunosuppressive medications and blood disorders may also elevate the risk of CDI ^{28,29}.

Understanding geographical variations in prevalence by studying CDI epidemiology and risk factors is essential for preventing, controlling, and managing the infection. In Latin America, and particularly in Argentina, comprehensive epidemiological data on CDI are limited. It has been reported that patients with diarrhea are not routinely tested for *C. difficile* in developing countries and, when tested, very often only the enzyme immunoassay (EIA) is used ^{30–32}. This could lead to an underestimation in the diagnosis and high economic burdens for the health system. Our retrospective study (2019-2023) assesses the prevalence of *C. difficile* among health care centers of the Northwest region of Buenos Aires, Argentina. Furthermore, with the aim to characterize our study cohort, we analyzed the demographic and clinical data of the patients and we conducted a meta-analysis to compare our findings with global reports.

Methodology

115

116

127

Human Samples and Participating Institutions

- The research was carried out in accordance with the Declaration of Helsinki (2013)
- and approved by the UNNOBA (Universidad Nacional del Noroeste de la Provincia
- de Buenos Aires) Ethics Committee (COENOBA).
- 120 Fecal samples from hospitalized adult patients with diarrhea were collected after
- obtaining informed consents and frozen at -20 °C until use. The samples were
- derived from the following health-care centers: Hospital Interzonal General de
- 123 Agudos (HIGA) Abraham Félix Piñeyro, Clínica Centro Médico Privada SRL and
- 124 Clínica IMEC. Samples received between January 1, 2019 and December 31, 2023
- from Sanitary Region III of Buenos Aires, Argentina (Supplementary Fig. 1) were
- included in this analysis.

Patients characterization

- The presence of *C. difficile* was determined in the fecal samples using a diagnostic
- algorithm (Supplementary Fig. 2) as recommended by Crobach et al. in 2016 ³³.
- Briefly, three tests were used in a retrospective approach: Enzyme immunoassay
- 131 (EIA, CoproStripTM C. difficile GDH + Toxin A + Toxin B (Savyon® Diagnostics Ltd)),
- Polymerase Chain Reaction from stool samples (PCR, Tag Phire Tissue Direct PCR
- 133 Master Mix (Thermo Fisher)) and Toxigenic culture (stool culture in CHROMAgarTM
- 134 *C. difficile* plates + PCR from isolated *C difficile* colonies).
- Patients were defined as CDI+ or CDI- and clinical, demographic and blood
- parameters were evaluated (**Table 1**).
- 137 CDI classifications by setting of acquisition and severity were defined according to
- the Infectious Diseases Society of America (IDSA) criteria ³⁴.

Clinical-demographical parameters	Blood parameters
Age	Leukocytes (cells/mm³)
Biological Sex	Neutrophils (cells/mm ³)
Previous hospitalization	Monocytes (cells/mm ³)
Previous consumption of Antibiotics	Lymphocytes (cells/mm ³)
Antibiotics use during hospitalization	Eosinophils (cells/mm ³)
Presence of comorbidities	Basophils (cells/mm ³)

Previous consumption of Proton Pump Inhibitors	Platelets (cells/mm ³)
Previous CDI	Urea (mg/dl)
Place of hospitalization	Creatinine (mg/dl)
Need for Intensive Care Unit (ICU)	Albumin (g/dl)
Origin	
Diarrhea classification	
Shock	
Death	

- **Table 1.** Clinical, demographic and blood parameters evaluated in CDI+ and CDIpatients.
- 142 Meta-analysis design
- A bibliographic search was carried out using PubMed and Google Scholar databases
- in addition to the Al SciSpace tool. The reports that fulfilled the definition criteria of
- cases and controls were selected. The meta-analysis workflow is summarized in Fig.
- 146 **4**.

147 Statistical Analysis

- 148 For clinical, demographic and blood parameters comparisons, parametric t-test or
- non-parametric Mann-Whitney test for unpaired samples were used. Fisher's exact
- test was used to analyze the frequency distribution of qualitative/nominal variables.
- Data was analyzed using GraphPad Prism 8.0.1 software (San Diego, CA, USA) and
- p values <0.05 were considered statistically significant.
- For the meta-analysis, the "Metafor" package from RStudio (2023.06.1+524 version)
- was used ³⁵. The Odds Ratio (OR, for categorical variables) and the Standardized
- 155 Mean Difference (SMD, for continuous variables) were calculated and a REML
- 156 (Random Effect Maximum Likelihood) model was employed. Models with a p value
- 157 <0.05 were considered as potential predictors of CDI incidence risk.</p>

Results and Discussion

CDI prevalence in Northwest Buenos Aires

- In Argentina, studies and reports on CDI are scarce and heterogeneous ^{36–39}. In
- order to contribute to a better understanding of the disease, we conducted a
- retrospective analysis of 249 fecal samples received between 2019-2023 from
- 163 Sanitary Region III of Buenos Aires.
- We determined *C. difficile* as the causal agent of one in five diarrheas (21.29%) **(Fig.**
- 165 1 a) and we detected that more than the 80% of the patients were infected with
- toxigenic strains; indicated by the presence of *C. difficile* Toxin B in the stool samples
- (Fig. 1 b). This percentage was similar to the worldwide reported prevalence, where
- 168 CDI is the underlying cause of 15 to 20% of diarrhea associated with the use of
- 169 antibiotics 40.

158

159

- When analyzing the cases on an annual basis, the frequency of CDI ranged around
- 20% from 2019 to 2023 (Fig. 1 c). Interestingly, the highest incidence in our study
- 172 cohort was observed during 2020, duplicating the percentage of CDI+ cases
- compared to the rest of the years (Fig. 1 c). In relation to this, the COVID-19
- pandemic brought about the preventive use of broad-spectrum antibiotics to avoid
- bacterial coinfections; which could be associated with the increase in detection 41–44.
- Nevertheless, CDI detection could have been impacted by the decrease in the
- number of tests, a fact that was corroborated in multiple studies carried out during
- the early stages of the pandemic 45-47. Additionally, there could also be an
- underestimation of CDI cases 48,49 since SARS-CoV-2 frequently causes
- gastrointestinal symptoms similar to those of C. difficile 50.
- 181 Regarding the severity of the diarrhea, all infected patients had a moderate
- classification (Fig. 1 d). Importantly, the majority of CDI infections occurred in the
- community setting (Fig. 1 e). 65.71% of the patients presented community-acquired
- 184 CDI, 14.29% in geriatric institutions and only the remaining 20% occurred in a
- hospital environment (Fig. 1 e). This is particularly notable, since the epidemiology
- of CDI has changed in the last two decades. The 027 strain, responsible for clinical
- outbreaks in the early 2000s ⁵¹, has recently decreased its incidence in part due
- fluoroguinolones restriction, prevention measures and to improvements in detection
- tests that have allowed a better characterization of the circulating ribotypes ^{52–56}.
- Additionally, an increase in strains associated with community infection (e.g. 078,
- 191 014 in Europe and 106 in the US) has been reported in recent years, with community-
- acquired cases rising above 40% ^{11,57–59}.

193

194




Figure 1. CDI prevalence in Northwestern Buenos Aires.

249 stool samples were evaluated using the diagnostic algorithm. a) Donut graph showing positive, negative and discordant results for the presence of *C. difficile*. b) Donut graph showing the percentage of toxigenic strains (presence of Toxin B) detected in the stool samples. c) CDI+ and CDI- results classified on an annual basis from 2019 to 2023. d) CDI classification. e) Origin of the CDI+ patients at the time of diagnosis.

Risk factors

After classifying the patients as CDI+ or CDI-, we determined the risk factors that could be involved in the prevalence of CDI.

As seen in **Fig. 2 a**, we found significant differences in the age of CDI+ and CDI-populations, with the CDI+ patients presenting a higher average age (CDI+: mean = 72 years vs. CDI-: mean = 65 years). By using a ROC curve analysis, we established a cut-off point of 69 years for advanced age as a risk factor in our cohort **(Fig. 2 b)**. Elderly patients have a greater probability of receiving broad-spectrum antibiotics, being hospitalized or staying longer in hospital settings partly due to the presence of comorbidities ^{60,61}.

- With age, the immune system decreases its functions and also older individuals
- 216 develop inflammageing, which could impact in the resolution of the infection; a fact
- 217 that was observed for neutrophils ⁶² and serum IgG against *C. difficile* toxins ^{63–65}.
- 218 Regarding biological sex, no differences were found for the proportion of males and
- 219 females between both patient populations (Fig. 2 c).
- 220 Consumption of antibiotics in the 3 months prior to the diagnosis of CDI, as well as
- previous hospitalizations and infections with *C. difficile*, could be considered risk
- factors that predisposes to CDI in our study cohort (Fig. 2 d, e and f). Hospitals and
- 223 healthcare facilities are common environments for *C. difficile* transmission since they
- can be easily colonized by spores that persist on surfaces for months ^{66,67}. Previous
- consumption of antibiotics is directly related to the dysbiosis of the microbiota that
- enables the colonization of *C. difficile* and is typically consider as the main risk factor
- for CDI ^{68,69}. Some antibiotics, such as clindamycin, broad-spectrum penicillins,
- cephalosporins and fluoroguinolones alter the microbiota to a greater extent than
- others ^{68,70,71}. When analyzing the families of antibiotics consumed by CDI+ patients,
- we observed that 56.52% had taken some kind of penicillin prior to diagnosis (Fig.
- 231 **2 g)**.
- On the other hand, the consumption of proton pump inhibitors (PPI) prior to diagnosis
- and the presence of comorbidities did not show significant differences between CDI-
- and CDI+ patients (Fig. 2 h and i). Fig. 2 j shows a breakdown of the comorbidities
- reported in the patients under study. Although they were analyzed individually, no
- substantial variations were found between the CDI+ and CDI- population for any of
- 237 them.

242

- No differences were found regarding the variables referring to the evolution of
- patients during admission to health centers such as hospitalization in common floor
- or ICU, need for ICU, shock and death (Supplementary Fig. 3).





Figure 2. CDI associated risk factors.

- Evaluation of risk factors associated with CDI. a) Age (years), b) ROC curve to
- 247 establish the age cut-off point, c) biological sex, d) prior antibiotics (ATB)
- consumption, e) prior hospitalization, f) prior CDI, g) antibiotic breakdown by family,
- 249 h) prior PPI consumption, i) comorbidities, j) breakdown of specific comorbidities (the
- 250 white number inside the bars represents the number of patients with the
- 251 comorbidity).

- a) Mann-Whitney test. c, d, e, f, h, and i) Fisher's exact test. Stacked bars represent
- 253 the percentage of patients for each parameter. ns= non-significant; *, p

Blood and serum parameters

- We also analyzed the patients' blood counts and serum parameters that were
- measured on the day of fecal sample collection.
- We observed a significant increase in the number of leukocytes (Fig. 3 a) and
- platelets (Fig. 3 j) in patients infected with *C. difficile*. When analyzing the count of
- 259 lymphocytes, monocytes and neutrophils individually between both patient
- 260 populations, although an increase was evident, we did not find significant differences
- (Fig. 3 b, c and d). However, it is important to note that CDI+ patients had increased
- at least two of these leukocyte populations compared to CDI- patients at the time of
- diagnosis (Fig. 3 e, f and g). Although some studies have highlighted that an
- elevated white blood cell (WBC) count is frequently observed in the context of CDI
- ⁷² ⁷³ ⁷⁴, little has been explored in using elevated WBC count as a predictor of this
- infection. In this regard, we agree with Vargas et al. ⁷⁵ in that the total leukocyte
- count alone is not a specific indicator for CDI. Previous work evaluating platelet count
- in CDI episodes reported controversial results, assigning them both a beneficial and
- detrimental role in relation to clinical symptoms ^{76–85}. We have recently shown that
- 270 platelets bind to C. difficile and promote its uptake by human macrophages using
- 271 macropinocytic pathways ⁸⁶. Therefore, we consider that platelets in CDI could be
- fundamental for the resolution of the infection and that further studies are needed to
- 273 unravel their role during CDI.
- 274 Regarding the rest of the blood parameters evaluated, while a significant decrease
- in basophils count was observed (Fig. 3 h), the eosinophil count was not affected by
- the presence of *C. difficile* (Fig. 3 i). To the best of our knowledge, to date there are
- 277 no reports on the role of basophils in CDI. Nevertheless, the potential role of CCL-5.
- a basophilic recruiter chemokine, has been highlighted in CDI 87,88
- No differences were evident for creatinine and albumin levels (Fig. 3 j and k), but
- an elevated urea concentration stood out in patients infected with C. difficile (Fig. 3
- 281 **m)**. Moreover, the BUN (Blood Urea Nitrogen)/Creatinine ratio was significantly
- elevated in CDI patients (Fig. 3 n). Elevated BUN ratios have been associated with
- complications of CDI ⁸⁹ as well as with higher mortality rates ⁹⁰ and high urea levels
- were also proposed as a risk factor for severe CDI ⁹¹.



- **Figure 3.** Blood and serum parameters in CDI+ and CDI- patients.
- Number of a) Leukocytes (cells/mm³), b) lymphocytes (cells/mm³), c) monocytes
- (cells/mm³), d) neutrophils (cells/mm³), e) lymphocytes plus monocytes (cells/mm³),
- 289 f) lymphocytes plus neutrophils (cells/mm³), g) neutrophils plus monocytes
- 290 (cells/mm³), h) basophils (cells/mm³), i) eosinophils (cells/mm³) and j) platelets
- (cells/mm³). Levels of k) creatinine (mg/dl), l) albumin (g/dl) and m) urea (mg/dl), n)
- 292 BUN (blood urea nitrogen)/creatinine ratio.
- a-i and k-n) Mann-Whitney test. j) unpaired t test. Violin plots show the distribution
- of the data. ns= non-significant; *, p<0.05; **, p<0.01.

Meta-analysis

286

295

303

304

305

306

307

We finally performed a meta-analysis to obtain more robust and reliable conclusions about the CDI associated parameters evaluated in our cohort. We defined the selection criteria (**Fig. 4 a**) and carried out a systematic review that allowed us to select 40 independent case/control type studies (**Table 2**) from the countries shown in light grey in **Fig. 4 b**.






Figure 4. Flow chart of the studies and countries screened and included in the Meta-analysis.

a) The obtained results regarding clinical and demographic characteristics of the CDI+ and CDI- patients in our cohort were contrasted against findings of other studies through a meta-analysis by RStudio package "Metafor". After initial identification, eligibility criteria were applied and 39 reports were included in the meta-analysis along with our data. CDI- patients were considered as the control group.

b) World map showing the countries from which the studies included in the metaanalysis come (light gray). The circles contain the number of studies selected per country.

Lopardo, G. et al, 2015 39 OUR study
Canada
Canada Lowe, D. O. et al, 2006 93 Dai, W. et al, 2020 94 Li, Y. et al, 2016 95 Lin, Y. et al, 2014 96 Lv, Z. et al, 2014 96 Tang, C. et al, 2018 97 Zhou, F, F, et al, 2014 98 Colombia Carvajal, C. et al, 2017 100 Denmark Soes, L. M. et al, 2014 101 France Le Monnier, A. et al, 2022 102 Hungary Kurti, Z. et al, 2015 103 Iceland Vesteinsdottir, I. et al, 2012 104 Ingle, M. et al, 2011 105 Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Mori, N. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2013 111 South Korea Han, S. H. et al, 2012 113; Lin
Dai, W. et al, 2020 94 Li, Y. et al, 2016 95 Lv, Z. et al, 2014 96 Tang, C. et al, 2018 97 Zhou, F, F, et al, 2014 98 Carvajal, C. et al, 2017 99 Salazar, C, L. et al, 2017 100 Denmark Soes, L. M. et al, 2014 101 France Hungary Le Monnier, A. et al, 2022 102 Hungary Kurti, Z. et al, 2015 103 Iceland Vesteinsdottir, I. et al, 2012 104 Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Japan Mori, N. et al, 2013 106 Japan Mori, N. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 Legenza, L. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
China Li, Y. et al, 2016 95 Lv, Z. et al, 2014 96 Tang, C. et al, 2018 97 Zhou, F, F, et al, 2014 98 Colombia Carvajal, C. et al, 2017 99 Salazar, C, L. et al, 2017 100 Soes, L. M. et al, 2014 101 France Le Monnier, A. et al, 2022 102 Hungary Iceland Vesteinsdottir, I. et al, 2015 103 Ingle, M. et al, 2011 105 Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Japan Mori, N. et al, 2015 107 Mexico Poland Czepiel, J. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 Legenza, L. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
China Lv, Z. et al, 2014 96 Tang, C. et al, 2018 97 Zhou, F, F, et al, 2014 98 Carvajal, C. et al, 2017 99 Salazar, C, L. et al, 2017 100 Denmark Soes, L. M. et al, 2014 101 France Le Monnier, A. et al, 2022 102 Hungary Kurti, Z. et al, 2015 103 Iceland Vesteinsdottir, I. et al, 2012 104 India Ingle, M. et al, 2011 105 Japan Mori, N. et al, 2013 106 Japan Morfin-Otero, R. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
Tang, C. et al, 2018 97 Zhou, F, F, et al, 2014 98 Carvajal, C. et al, 2017 99 Salazar, C, L. et al, 2017 100 Denmark France Le Monnier, A. et al, 2022 102 Hungary Iceland Vesteinsdottir, I. et al, 2012 104 India India Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Japan Mori, N. et al, 2015 107 Mexico Poland South Africa South Korea Taiwan Tang, C. et al, 2014 98 Carvajal, C. et al, 2017 100 Soes, L. M. et al, 2014 101 Le al, 2022 102 Legenza, L. et al, 2015 107 Rajabally, N. et al, 2016 108 Rajabally, N. et al, 2013 111 Lee, Y. C. et al, 2012 113; Lin
Zhou, F, F, et al, 2014 98 Carvajal, C. et al, 2017 99 Salazar, C, L. et al, 2017 100 Denmark Soes, L. M. et al, 2014 101 France Hungary Iceland Vesteinsdottir, I. et al, 2012 104 India Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Japan Mori, N. et al, 2015 107 Mexico Poland South Africa South Korea Taiwan Zhou, F, F, et al, 2017 99 Carvajal, C. et al, 2017 100 Soes, L. M. et al, 2014 101 Le Monnier, A. et al, 2012 102 Let al, 2015 103 Ingle, M. et al, 2013 106 Ingle, M. et al, 2013 106 Czepiel, J. et al, 2016 108 Rajabally, N. et al, 2018 110 Rajabally, N. et al, 2013 111 Lee, Y. C. et al, 2012 113; Lin
Colombia Carvajal, C. et al, 2017 100 Denmark Soes, L. M. et al, 2014 101 France Le Monnier, A. et al, 2022 102 Hungary Kurti, Z. et al, 2015 103 Iceland Vesteinsdottir, I. et al, 2012 104 India Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Ingle, M. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2013 111 Rajabally, N. et al, 2013 111 Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
Colombia Salazar, C, L. et al, 2017 100 Denmark Soes, L. M. et al, 2014 101 France Le Monnier, A. et al, 2022 102 Hungary Kurti, Z. et al, 2015 103 Iceland Vesteinsdottir, I. et al, 2012 104 India Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Mori, N. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
Denmark Soes, L. M. et al, 2014 101 France Le Monnier, A. et al, 2022 102 Hungary Kurti, Z. et al, 2015 103 Iceland Vesteinsdottir, I. et al, 2012 104 India Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Mori, N. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
France Le Monnier, A. et al, 2022 102 Hungary Kurti, Z. et al, 2015 103 Iceland Vesteinsdottir, I. et al, 2012 104 Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Japan Mori, N. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
Hungary Kurti, Z. et al, 2015 103 Iceland Vesteinsdottir, I. et al, 2012 104 India Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Ingle, M. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 Rajabally, N. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
Iceland Vesteinsdottir, I. et al, 2012 104 India Ingle, M. et al, 2011 105 Japan Mori, N. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
India Ingle, M. et al, 2011 105 Ingle, M. et al, 2013 106 Japan Mori, N. et al, 2015 107 Mexico Poland South Africa South Korea Ingle, M. et al, 2013 106 Morfin-Otero, R. et al, 2015 107 Czepiel, J. et al, 2014 109 Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
Ingle, M. et al, 2013 106 Japan Mori, N. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
Japan Mori, N. et al, 2015 107 Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
Mexico Morfin-Otero, R. et al, 2016 108 Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
Poland Czepiel, J. et al, 2014 109 South Africa Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
South Africa Legenza, L. et al, 2018 110 Rajabally, N. et al, 2013 111 Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
South Korea Han, S. H. et al, 2014 112 Lee, Y. C. et al, 2012 113; Lin
C. Y. et al, 2022 114
Thailand Thipmontree, W. et al, 2011 115
Turkey Ergen, E. K. et al, 2009 116
Diai, 5. et ai, 2005
Dial, S. et al, 2008 ¹¹⁸
United Kingdom Marwick, C. A. et al, 2013 119
Suissa, D. et al, 2012 ¹²⁰ Wilcox, M. H. et al, 2008 ¹²¹
Wilcox, M. H. et al, 2008 ¹²¹ Baxter, R. et al, 2008 ¹²²
Haddad, F. G. et al, 2019 123
Kuntz, J. L. et al, 2011 124
Kutty P K et al. 2010 125
United States Kwon, S. et al, 2017 126
Naggie, S. et al, 2011 ¹²⁷
Tabak, P. Y. et al, 2015 128
Tartof, S. Y. et al, 2015 129

Table 2. Countries and studies included in the meta-analysis.

The effects for each of the variables evaluated in the meta-analysis are summarized in **Table 3**.

331	RISK PREDICTOR	OR
	Age	1,19 **
332	Biological sex	0,89 *
	Prior ATB consumption	3,02 ***
333	Prior PPI consumption	1,29 ns
	Prior hospitalization	2,45 ***
334	Prior CDI	1,76 ns
	WBC (10 ⁹ cel/mm ³)	1,35 *
335	Platelets (10 ⁹ cel/ mm ³)	1,54 ns
	Comorbidities	
336	Diabetes <i>mellitus</i>	1,26 ns
	Heart disease	1,41 *
337	Kidney disease	2,23 ***
	HIV	1,00 ns
338		

Table 3. Summary of risk predictors from the meta-analysis.

The dataset included 11,596 individuals with CDI and 536,467 matched controls (Table 4). Overall, the distribution of biological sex was 40.06% male vs. 59.94% female, being 44.33% vs. 55.67% in the CDI+ population and 39.98% vs. 60.02% in the control group. The demographic parameters Age (OR= 1.19; 95% CI, 1.06 to 1.35) and Biological Sex (OR= 0.89; 95% CI, 0.81 to 0.99) obtained significant models, which implies that, globally, advanced age and female biological sex are associated with a higher risk of CDI (Fig. 5 a and b).

9.11% of the included individuals were previously exposed to antibiotics and 22.18% to PPI. Both antibiotic (CDI+ 39.95% vs. CDI- 8.52%) and PPI (CDI+ 29.87% vs. CDI- 21.76%) consumption was higher among those patients infected with *C. difficile* (Table 4). In this analysis, which ignored antibiotic subclasses, we found that the pooled impact of any antibiotic exposure (OR= 3.02; 95% CI, 2.32 to 3.94) increased the risk of CDI by a multiple of 3 (Fig. 5 c). A longer duration of antibiotic therapy, as well as a greater number of antibiotics administered increase the probability of CDI ⁷⁰. The risk of acquiring CDI could be 8 to 10 times higher during antibiotic therapy, even three months after its completion, with the first month being the one with the highest risk ¹³⁰.

Regarding PPIs as risk factors for CDI, there is an arduous discussion with some reports showing around 40-71.4% of hospitalized patients received PPI therapy during hospitalization ^{131–133} and others supporting the idea that PPIs could trigger long-term adverse effects trough changes on the microbiota composition ^{134,135}. In our meta-analysis, there was no evidence of the impact of PPI on CDI risk **(Fig. 5 d)**.

Previous hospitalization emerged as the second most influential predictor for CDI risk (OR= 2.46; 95% CI, 1.90 to 3.17) (Fig. 5 e). Among the CDI+ patients included in the meta-analyses, 27.88% had been hospitalized prior to diagnosis (Table 4) while only 16.80% in the control group.

Previous episodes of CDI are widely reported as a risk factor for subsequent cases and/or recurrences in patients. However, in this meta-analysis previous CDI was not a predictor of risk (**Fig. 5 f**) which could be attributed to the fact that only 4 of the 40 included studies provided this type of data ^{56,103,120,123}. Actually, when evaluating the Forest Plot for this variable in detail, the studies show the same trend as our epidemiological study when considering previous CDI as a risk factor.

When evaluating comorbidities, both heart diseases (OR= 1.41; 95% CI, 1.02 to 1.94) and chronic kidney disease (OR= 2.23; 95% CI, 1.38 to 3.61) exhibited models with significant effects (**Fig. 5 g and h**), indicating that these pathologies increase the risk of CDI. The rest of the tested comorbidities were not associated with a higher risk of infection (**Fig. 5 i and j**). The presence of comorbidities has been widely reported as a condition that facilitates colonization and infection by *C. difficile* ¹³⁶. A previous meta-analysis found IBD, diabetes, leukemia or lymphoma, kidney failure and solid cancer as the CDI risk-related comorbidities ¹³⁷.


Finally, blood parameters were analyzed. Increased leukocytes count was also a potential predictor of CDI according to our comparative analysis (OR= 1.36; 95% CI, 1.05 to 1.75) (Fig. 5 k). Although the number of platelets did not show a statistically significant effect (Fig. 5 l), it is important to note that only 2 studies apart from ours evaluated this parameter.

387			CDI+	CDI-	TOTAL
202	N° of individuals		11596	536467	548467
388	Sav	Male	44.33%	39.98%	40.06%
389	Sex	Female	55.67%	60.02%	59.94%
	Prior ATB consumption	With	39.95%	8.52%	9.11%
390		Without	60.05%	91.48%	90.89%
391	Prior PPI consumption	With	29.87%	21.76%	22.18%
		Without	70.13%	78.24%	77.82%
392	Drier beenitelization	With	27.88%	16.80%	17.07%
	Prior hospitalization	\\/ithout	72 120/	02 200/	on 020/

Table 4. Meta-analysis dataset.

TOTAL

Without 72.12% 83.20% 82.93%



- 397 **Figure 5** Forest plots of risk predictors.
- Forest plots representative of each variable evaluated in the meta-analysis. a) Age,
- b) biological sex, c) previous ATB consumption, d) previous PPI consumption, e)
- 400 prior hospitalization, f) prior CDI, g) heart disease, h) chronic kidney disease, i)
- diabetes mellitus, j) HIV, k) white blood cells (WBC) count (cells/mm³), l) platelets
- 402 count (cells/mm³).

- 403 A REML (Random Effect Maximum Likelihood, gray diamond) random effects model
- was applied. Models with p<0.05 (OR/SMD ± CI values less or greater than 1) were
- considered as potential risk predictors for CDI. Black diamonds represent the means
- of each of the variables in each study. Bars indicate the lower and upper confidence
- extremes. Our study (white diamond) is mentioned as OUR STUDY.
- OR= odds ratio. SMD= standard media deviation. CI= confidence interval

410 Conclusions

- We have defined risk factors associated with CDI and detected modulations in
- different blood parameters in our study cohort in Argentina. We have also explored
- 413 the relevance of our findings at a global level by a systematic review and meta-
- analysis. Our results emphasize the need to detect C. difficile as a causal agent of
- 415 infectious diarrhea in a country where testing is not standardized or routinely
- performed in the health institutions. Our report provides valuable insights that could
- contribute to a more efficient surveillance of CDI, diagnosis and follow-up of patients.

418 Author contributions

- 419 Conceptualization: all authors
- 420 Formal analysis: AMB, NDM, JC, SP, LSM and REHDP.
- 421 Funding acquisition: AMB, SP, REHDP and VP.
- Investigation: AMB, NDM, SP, REHDP and VP.
- 423 Methodology: all authors.
- 424 Software: NDM and REHDP.
- 425 Supervision: REHDP and VP.
- Writing: AMB wrote the original draft. All authors contributed to the review & editing
- 427 of this manuscript.

428 Role of the funding source

- This work was supported by Universidad Nacional del Noroeste de la Provincia de
- Buenos Aires [grant numbers SIB 0618/2019, SIB 2113/2022 and "Proyectos de
- Investigación Interdisciplinarios de la UNNOBA" Res. CS 2190/2022, to VP].
- 432 Agencia Nacional de Promoción Científica y Tecnológica, Fondo para la
- Investigación Científica y Tecnológica [ANPCyT-FONCyT, grant numbers PICT A
- 434 2017-1896 and PICT-2021-I-A-01119 to VP; PICT 2018-03084 IB to RHDP, PICT-
- 435 2021-I-INVI-00584 to AB and PICT-2021-I-INVI-00208 to SP]. UNNOBA FONCyT
- 436 [grant number PICTO 2019-00007 to RHDP and VP]. Consejo Nacional de
- 437 Investigaciones Científicas y Técnicas [CONICET, grant number PIP 2021
- 438 11220200103137CO to VP and RHDP].

Acknowledgements

- We thank all the patients who voluntarily participated of this study. We also thank
- Natalia Menite, Lucia Romano and Gastón Villafañe for their technical assistance.
- We acknowledge the laboratory personnel, medical staff and biochemists who have
- collaborated in the collection of samples and data during the study period of this
- report. Finally, we thank Flaticon for the icons used in the graphical abstract of this
- 445 work.

446 References

- 447 1. Brazier JS. . 1998;47–57.
- 2. Zhang S, Palazuelos-Munoz S, Balsells EM, et al. . *BMC Infect Dis*;16 . Epub ahead of print 2016. DOI: 10.1186/s12879-016-1786-6.
- 450 3. Center for Disease Control and Prevention. . *CDC*;10 . Epub ahead of print 2019. DOI: 10.1186/s13756-020-00872-w.
- 452 4. Smits WK, Lyras D, Lacy DB, et al. . DOI: 10.1038/nrdp.2016.20.
- 5. Feuerstadt P, Theriault N, Tillotson G. . BMC Infect Dis. 2023;23:1–8.
- 454 6. Di X, Bai N, Zhang X, et al. . *Brazilian J Infect Dis.* 2015;19:339–349.
- 455 7. Bainum TB, Reveles KR, Hall RG, et al. . *Microorganisms*. 2023;11:1–22.
- 456 8. Phanchana M, Harnvoravongchai P, Wongkuna S, et al. . *World J*457 *Gastroenterol*. 2021;27:7210–7232.
- 458 9. Burke KE, Lamont JT. . Gut Liver. 2014;8:1–6.
- 459 10. Freeman J, Bauer MP, Baines SD, et al. . *Clinical Microbiology Reviews*. 2010;23:529–549.
- 461 11. Goorhuis A, Bakker D, Corver J, et al. . *Clin Infect Dis.* 2008;47:1162–1170.
- 12. Chitnis AS, Holzbauer SM, Belflower RM, et al. . *JAMA Intern Med.* 2013;173:1359–1367.
- 466 14. Gupta A, Khanna S. . *Infect Drug Resist*. 2014;7:63–72.
- 467 15. Alice Y. Guh, MD, MPH and Preeta K. Kutty, MD M. . *Physiol Behav*.
 468 2019;169:248–256.
- 16. Lawler AJ, Lambert PA, Worthington T. . *Trends Microbiol*. 2020;28:744–752.
- 471 17. Paredes-Sabja D, Shen A, Sorg JA. . Trends Microbiol. 2014;22:1–15.
- 472 18. Hernández Del Pino RE, Barbero AM, Español LÁ, et al. . *J Leukoc Biol*. 473 2021;109:195–210.
- 474 19. Lim SC, Knight DR, Riley T V. . Clin Microbiol Infect. 2020;26:857–863.
- 475 20. Donskey CJ. . Clin Infect Dis. 2010;50:1458–1461.
- 21. Dicks LMT. . *Microorganisms*;11 . Epub ahead of print 2023. DOI: 10.3390/microorganisms11092161.
- 478 22. Czepiel J, Dróżdż M, Pituch H, et al. . *Eur J Clin Microbiol Infect Dis Off* 479 *Publ Eur Soc Clin Microbiol.* 2019;38:1211–1221.

- 480 23. Huang CH, Tseng YH, Tsai WS, et al. . *Infect Dis Ther* . Epub ahead of print 2024. DOI: 10.1007/s40121-024-00922-5.
- 482 24. Song JH, Kim YS. . Gut Liver. 2019;13:16–24.
- 483 25. Nitzan O, Elias M, Chazan B, et al. . *World J Gastroenterol*. 2013;19:7577–484 7585.
- 485 26. Qu H-Q, Jiang Z-D. . Diabetes Res Clin Pract. 2014;105:285–294.
- 486 27. Dudzicz S, Wiecek A, Adamczak M. . J Clin Med. 2021;10:1–13.
- 28. Sartelli M, Malangoni MA, Abu-Zidan FM, et al. . *World J Emerg Surg*. 2015;10:1–23.
- 489 29. Khanna S, Pardi DS. . Mayo Clin Proc. 2012;87:1106–1117.
- 490 30. Curcio D, Cané A, Fernández FA, et al. . Infect Dis Ther. 2019;8:87-103.
- 491 31. Roldan GA, Cui AX, Pollock NR. . *J Clin Microbiol*;56 . Epub ahead of print March 2018. DOI: 10.1128/JCM.01747-17.
- 493 32. Acuña-Amador L, Quesada-Gómez C, Rodríguez C. . *Anaerobe*;74 . Epub ahead of print 2022. DOI: 10.1016/j.anaerobe.2022.102547.
- 495 33. Crobach MJT, Planche T, Eckert C, et al. . *Clin Microbiol Infect*. 2016;22:S63–S81.
- 497 34. Johnson S, Lavergne V, Skinner AM, et al. . *Clin Infect Dis.* 2021;73:e1029–498 e1044.
- 499 35. Viechtbauer W. . J Stat Softw. 2010;36:1–48.
- 500 36. Fernandez Canigia L, Nazar J, Arce M, et al. . *Rev Argent Microbiol*. 2001;33:101–107.
- 502 37. Legaria MC, Lumelsky G, Rosetti S. . *Anaerobe*. 2003;9:113–116.
- 503 38. Goorhuis A, Legaria MC, van den Berg RJ, et al. . *Clin Microbiol Infect*. 2009;15:1080–1086.
- 505 39. Lopardo G, Morfin-Otero R, Moran-Vazquez II, et al. . *Brazilian J Infect Dis*. 2015;19:8–14.
- 507 40. Bartlett JG, Gerding DN. . *Clinical Infectious Diseases*;46 . Epub ahead of print January 2008. DOI: 10.1086/521863.
- 509 41. Pan L, Mu M, Yang P, et al. . *Am J Gastroenterol.* 2020;115:766–773.
- 510 42. Granata G, Petrosillo N, Al Moghazi S, et al. . *Anaerobe*. 2022;74:102484.
- Huttner BD, Catho G, Pano-Pardo JR, et al. . *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.* 2020;26:808–810.
- 513 44. Chen N, Zhou M, Dong X, et al. . Lancet (London, England). 2020;395:507-

- 514 513.
- 515 45. Adams-Sommer V, Fu Y, Grinspan LT, et al. . Infect Control Hosp Epidemiol.
- 516 2021;42:1165–1166.
- 517 46. Laszkowska M, Kim J, Faye AS, et al. . *Dig Dis Sci.* 2021;66:4398–4405.
- 518 47. Hawes AM, Desai A, Patel PK. . Anaerobe. 2021;70:102384.
- 519 48. Luo M, Liu Y, Wu P, et al. . 8 . Epub ahead of print 2017. DOI:
- 520 10.3389/fphys.2017.00822.
- 521 49. Khanna S, Kraft CS. . Future Microbiol. 2021;16:439–443.
- 522 50. Tariq R, Saha S, Furqan F, et al. . *Mayo Clin Proc.* 2020;95:1632–1648.
- 523 51. Louie TJ, Cannon K, Byrne B, et al. . Clin Infect Dis an Off Publ Infect Dis
- 524 Soc Am. 2012;55 Suppl 2:S132-42.
- 525 52. Guh AY, Mu Y, Winston LG, et al. . N Engl J Med. 2020;382:1320–1330.
- 526 53. Gentry CA, Williams RJ 2nd, Campbell D. . Diagn Microbiol Infect Dis.
- 527 2021;100:115308.
- 528 54. McDermott LA, Thorpe CM, Goldstein E, et al. . Open Forum Infect Dis.
- 529 2022;9:ofac492.1299.
- 530 55. Dingle KE, Didelot X, Quan TP, et al. . Lancet Infect Dis. 2017;17:411–421.
- 531 56. Wilcox MH, Shetty N, Fawley WN, et al. . Clin Infect Dis. 2012;55:1056-
- 532 1063.
- 533 57. Khanna S, Pardi DS, Aronson SL, et al. . *Am Coll Gastroenterol*;107.
- 534 58. European Centre for Disease Prevention and Control. . *Annu Epidemiol Rep*
- 535 Commun Dis Eur. 2016;40:335–348.
- 536 59. Carlson TJ, Blasingame D, Gonzales-Luna AJ, et al. . *Anaerobe*.
- 537 2020;62:102142.
- 538 60. Kincaid SE. . Consult Pharm J Am Soc Consult Pharm. 2010;25:834–836.
- 539 61. Owens RC. . Drugs. 2007;67:487-502.
- 540 62. Bassaris HP, Lianou PE, Legakis NJ, et al. . *Med Microbiol Immunol*.
- 541 1984;173:49–55.
- 542 63. Nakamura S, Mikawa M, Nakashio S, et al. . *Microbiol Immunol*.
- 543 1981;25:345–351.
- 64. Bacon AE, Fekety R. Diagn Microbiol Infect Dis. 1994;18:205–209.
- 545 65. Simor AE, Bradley SF, Strausbaugh LJ, et al. . *Infect Control Hosp*
- 546 Epidemiol. 2002;23:696–703.
- 547 66. Guerrero DM, Nerandzic MM, Jury LA, et al. . Am J Infect Control.

- 548 2012;40:556–558.
- 549 67. Edwards AN, Karim ST, Pascual RA, et al. . Front Microbiol. 2016;7:1698.
- 550 68. Clark T, Wiselka M. . Clin Med. 2008;8:544–547.
- 551 69. Schroeder MS. . *Am Fam Physician*. 2005;71:921–928.
- 552 70. Hessen MT. . Ann Intern Med. 2010;153:ITC41-15; quiz ITC416.
- 553 71. Dubberke ER, Wertheimer Al. . *Infect Control Hosp Epidemiol.* 2009;30:57–554 66.
- 555 72. Wanahita A, Goldsmith EA, Marino BJ, et al. . *Am J Med*. 2003;115:543–546.
- 556 73. Wanahita A, Goldsmith EA, Musher DM. . *Clin Infect Dis an Off Publ Infect Dis Soc Am.* 2002;34:1585–1592.
- 558 74. Bulusu M, Narayan S, Shetler K, et al. . *Am J Gastroenterol.* 2000;95:3137–3141.
- 560 75. Vargas E, Apewokin S, Madan R. . *Anaerobe*. 2017;45:101–105.
- 561 76. Mihăilă RG, Cătană C, Olteanu AL, et al. . *Biomarkers*. 2019;24:389–393.
- 562 77. Buchrits S, Gafter-Gvili A, Bishara J, et al. . *J Clin Med*;10 . Epub ahead of print July 2021. DOI: 10.3390/jcm10132957.
- 564 78. Lee DY, Chung EL, Guend H, et al. . *Ann Surg.* 2014;259:148–156.
- 565 79. Byrn JC, Maun DC, Gingold DS, et al. . *Med Hist*. 2012;143:150–154.
- 80. Nseir W, Khamisy-Farah R, Amara A, et al. . *Isr Med Assoc J.* 2019;21:658–661.
- 568 81. Allegretti JR, Marcus J, Storm M, et al. . *Dig Dis Sci.* 2020;65:1761–1766.
- 569 82. Zhao L, Luo Y, Bian Q, et al. . *Infect Drug Resist*. 2020;13:171–181.
- 570 83. Pant C, Madonia PN, Jordan P, et al. . *J Investig Med*. 2009;57:40–42.
- 571 84. Yan D, Chen Y, Lv T, et al. . *J Med Microbiol*. 2017;66:1483–1488.
- 572 85. Phanchana M, Phetruen T, Harnvoravongchai P, et al. . *Sci Rep.* 2020;10:1–573 8.
- 574 86. Barbero AM, Hernández Del Pino RE, Fuentes F, et al. . 2024;1–14.
- 575 87. Rao K, Erb-Downward JR, Walk ST, et al. . *PLoS One*. 2014;9:e92578.
- 576 88. Abhyankar MM, Ma JZ, Scully KW, et al. . Am Soc Microbiol. 2020;11:1–10.
- 89. Abou Chakra CN, McGeer A, Labbe AC, et al. . *Clin Infect Dis*.
- 578 2015;61:1781–1788.
- 579 90. Sartelli M, Di Bella S, McFarland L V., et al. . *World J Emerg Surg*. 2019;14:1–29.

- 581 91. Bermejo Boixareu C, Tutor-Ureta P, Ramos Martínez A. . *Rev Esp Geriatr* 682 *Gerontol.* 2020;55:225–235.
- 583 92. Lopes Cançado GG, Silveira Silva RO, Rupnik M, et al. . *Anaerobe*. 2018;54:65–71.
- 585 93. Lowe DO, Mamdani MM, Kopp A, et al. Proton Pump Inhibitors and Hospitalization for Clostridium Difficile-Associated Disease: A Population-Based Study.
- 588 94. Dai W, Yang T, Yan L, et al. . *BMC Infect Dis*;20 . Epub ahead of print April 2020. DOI: 10.1186/s12879-020-05014-6.
- 590 95. Li Y, Huang Y, Li Y, et al. . *Pakistan J Med Sci.* 2016;32:736–741.
- 591 96. Lv Z, Peng GL, Su JR. . *Brazilian J Med Biol Res.* 2014;47:1085–1090.
- 592 97. Tang C, Li Y, Liu C, et al. . *Am J Infect Control*. 2018;46:285–290.
- 593 98. Zhou FF, Wu S, Klena JD, et al. . *Eur J Clin Microbiol Infect Dis*.
 594 2014;33:1773–1779.
- 595 99. Carvajal C, Pacheco C, Jaimes F. . *Biomedica*. 2017;37:53–61.
- 596 100. Salazar CL, Reyes C, Atehortua S, et al. . *PLoS One*;12 . Epub ahead of print September 2017. DOI: 10.1371/journal.pone.0184689.
- 101. Soes LM, Holt HM, Böttiger B, et al. . *Epidemiol Infect*. 2014;142:1437–1448.
- 599 102. Le Monnier A, Candela T, Mizrahi A, et al. . *J Hosp Infect*. 2022;129:65–74.
- 103. Kurti Z, Lovasz BD, Mandel MD, et al. . World J Gastroenterol.
 2015;21:6728–6735.
- 104. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, et al. . *Eur J Clin Microbiol Infect Dis.* 2012;31:2601–2610.
- 105. Ingle M, Deshmukh A, Desai D, et al. . *Indian J Gastroenterol*. 2011;30:89–
 93.
- 106. Ingle M, Deshmukh A, Desai D, et al. . *Indian J Gastroenterol*. 2013;32:179–183.
- 608 107. Mori N, Aoki Y. . *J Infect Chemother*. 2015;21:864–867.
- 609 108. Morfin-Otero R, Garza-Gonzalez E, Aguirre-Diaz SA, et al. . *Brazilian J Infect Dis*. 2016;20:8–13.
- 109. Czepiel J, Biesiada G, Brzozowski T, et al. . *J Physiol Pharmacol an Off J Polish Physiol Soc.* 2014;65:695–703.
- 110. Legenza L, Barnett S, Rose W, et al. . *BMJ Glob Heal*;3 . Epub ahead of print July 2018. DOI: 10.1136/bmjgh-2018-000889.
- 111. Rajabally N, Pentecost M, Pretorius G, et al. . South African Med J.

- 616 2013;103:168–172.
- 112. Han SH, Kim H, Lee K, et al. . *J Med Microbiol*. 2014;63:1542–1551.
- 113. Lee YC, Wang JT, Chen AC, et al. . *J Microbiol Immunol Infect*.
 2012;45:287–295.
- 114. Lin C-Y, Cheng H-T, Kuo C-J, et al. . *Microbiol Spectr*;10 . Epub ahead of print August 2022. DOI: 10.1128/spectrum.00486-22.
- 115. Thipmontree W, Kiratisin P, Manatsathit S, et al. Epidemiology of Suspected Clostridium difficile-Associated Hospital-Acquired Diarrhea in Hospitalized
- Patients at Sirirai Hospital. 2011.
- 116. Ergen EK, Akalin H, Yilmaz E, et al. . *Med Mal Infect*. 2009;39:382–387.
- 117. Dial S, Delaney JAC, Barkun AN, et al. . JAMA. 2005;294:2989–2995.
- 118. Dial S, Kezouh A, Dascal A, et al. . C Can Med Assoc J. 2008;179:767–772.
- 119. Marwick CA, Yu N, Lockhart MC, et al. . *J Antimicrob Chemother*.
 2013;68:2927–2933.
- 120. Suissa D, Delaney JAC, Dial S, et al. . *Br J Clin Pharmacol*. 2012;74:370–375.
- 632 121. Wilcox MH, Mooney L, Bendall R, et al. . *J Antimicrob Chemother*. 2008;62:388–396.
- Baxter R, Ray GT, Fireman BH. . *Infect Control Hosp Epidemiol*.2008;29:44–50.
- 123. Haddad FG, Zaidan J, Polavarapu A, et al. . *Z Gastroenterol*. 2019;57:1183–
 1195.
- 638 124. Kuntz JL, Chrischilles EA, Pendergast JF, et al. . *BMC Infect Dis*;11 . Epub ahead of print July 2011. DOI: 10.1186/1471-2334-11-194.
- 125. Kutty PK, Woods CW, Sena AC, et al. . *Emerg Infect Dis.* 2010;16:197–204.
- 126. Kwon SS, Gim JL, Kim MS, et al. . *Anaerobe*. 2017;48:42–46.
- 127. Naggie S, Miller BA, Zuzak KB, et al. . *Am J Med*;124 . Epub ahead of print
 March 2011. DOI: 10.1016/j.amjmed.2010.10.013.
- 128. Tabak YP, Johannes RS, Sun X, et al. . *Infect Control Hosp Epidemiol*. 2015;36:695–701.
- 129. Tartof SY, Rieg GK, Wei R, et al. . *Infect Control Hosp Epidemiol*.
 2015;36:1409–1416.
- 130. Hensgens MPM, Goorhuis A, Dekkers OM, et al. . *J Antimicrob Chemother*. 2012;67:742–748.
- 131. Nardino RJ, Vender RJ, Herbert PN. . Am J Gastroenterol. 2000;95:3118-

651 3122.

- 132. Herzig SJ, Howell MD, Ngo LH, et al. . *JAMA*. 2009;301:2120–2128.
- 133. Pham CQD, Regal RE, Bostwick TR, et al. . *Ann Pharmacother*.2006;40:1261–1266.
- 134. Freedberg DE, Lebwohl B, Abrams JA. . Clin Lab Med. 2014;34:771–785.
- 135. Singh A, Cresci GA, Kirby DF. . Nutr Clin Pract Off Publ Am Soc Parenter
 Enter Nutr. 2018;33:614–624.
- 136. van Prehn J, Reigadas E, Vogelzang EH, et al. . *Clin Microbiol Infect*.
 2021;27:S1–S21.
- 137. Furuya-Kanamori L, Stone JC, Clark J, et al. . *Infect Control Hosp Epidemiol*.
 2015;36:132–141.

Figure 1. CDI prevalence in Northwest Buenos Aires.




Figure 2. CDI associated Risk factors.




Figure 3. Blood and serum parameters in CDI+ and CDI-patients.




Figure 4. Flow chart of studies screened and included in the meta-analysis and countries included in the meta-analysis.





Figure 5. Forestplots of risk predictors. Prior ATB consumption b) a) Carvajal, C. et al., 2017-Czepial, J. et al., 2014-Dial, S. et al., 2005-Dial, S. et al., 2005-Raddad, F. G. et al., 2019-Han, S. H. et al., 2014-ingle, M. et al., 2011-ingle, M. et al., 2011-Lee, Y. C. et al., 2012-Li, Y. et al., 2016-Li, C. Y. et al., 2016-Lin, C. Y. et al., 2016-Lin, C.-Y. et al. 2022-Cangado, G. G. et al. 2018-Lowe, D. O. et al. 2006-Lv, Z. et al. 2014-Marwick, C. A. et al. 2013-OUR STUDY-Tang, C. et al, 2018 Tartof, S. Y. et al, 2015 REML f = 92.64%, p = 0.0029 SMD d) f) e) Prior CDI 100 M at 15 191 1854, M. of ot, 2911 Haddad, F. G. et al, 2019-Kurti, Z. et al, 2015 -OUR STUDY Suissa, D. et al, 2012 DUN EFOO M. at at, 291 Wilcox, M. H. et al, 2008 REML -20 20 40 80 100 12 = 90,39%, p = 0.6198 OR h) i) g) Chronic Kidney Disea Lagrana, L. et al., 2015 Lowe, E. O. et al, 200 tin Otero, R. et al. 201 GON STOO Setupor, C. L. at at, 281 Balance, B. et al., 201 THE C M. M. 197 REM F-86805, p+80005 j) k) I) Platelets count WBC HIV Carvajal, C. et al, 2017-Czepiel, J. et al. 2014 Czepiel, J. ot al, 2014 Ingle, M. et al, 2013 Han, S. H. et al, 2014-Legenza, L. et al, 2018 Kurti, Z. et al. 2015-Lin. C. Y. et al. 2022 OUR STUDY Lee, Y. C. et al, 2012 Rajabelly, N. et at, 2012 Li. Y. et al. 2016 OUR STUDY Lin, C.-Y. et al. 2022-Lv, Z. et al, 2014 REMI OUR STUDY f² = 38,13%, p = 0.9939 OR f² = 81,78%, p = 0.0598 SMD

f = 84,86%, p = 0.0101


SMD



- Hospital Interzonal General de Agudos Abraham Piñeyro
- C.P.A.: Provincial Center for Addiction Care

Supplementary Figure 1. Sanitary Region III of Buenos Aires, Argentina.

Sanitary region from the northwest of Buenos Aires province (Argentina) comprised of the municipalities of: Chacabuco, F. Ameghino, General Arenales, General Pinto, General Viamonte, Junín, Leandro N. Alem and Lincoln.




Supplementary Figure 2. Diagnostic algorithm to determine *C. difficile* presence in stool samples.

A cohort of 249 patients with gastrointestinal symptoms and diarrhea was evaluated. The presence of *C. difficile* within stool samples was ascertained by an algorithm that includes 3 tests (EIA, PCR, and toxigenic culture), accompanied by an exhaustive analysis of the patients' medical records. This algorithm was designed based on Crobach et al. recommendations ¹.

GDH, glutamate dehydrogenase from C. difficile.

Supplementaryfigure 3. Clinical data from CDI+ and CDI- patients.




Supplementary Figure 3. Clinical data from CDI+ and CDI- patients.

After classifying the patients into CDI+ or CDIpopulations using the diagnostic algorithm, data from clinical records was evaluated. a) Type of hospitalization room b) requirement of ICU, c) diarrhea classification d) presence of shock, e) death, f) precedence of the patients, g) CDI origin in both populations.

ICU= Intensive Care Unit. HO= Hospital-acquired CDI. CO= Community-acquired CDI. CO-HCFA= Community-acquired CDI associated to hospital environments.

a, b, c, d, e) Fisher's exact test; f, g) Chi-square test with Kruskal Wallis test. ns= non-significant



 $\textbf{Table 1.} \ \textbf{Clinical, demographic and blood parameters in CDI+ and CDI- patients.}$

Clinical-demographical parameters	Blood parameters
Age	Leukocytes (cells/mm³)
Biological Sex	Neutrophils (cells/mm³)
Previous hospitalization	Monocytes (cells/mm³)
Previous consumption of Antibiotics	Lymphocytes (cells/mm³)
Antibiotics use during hospitalization	Eosinophils (cells/mm³)
Presence of comorbidities	Basophils (cells/mm ³)
Previous consumption of Proton Pump Inhibitors	Platelets (cells/mm³)
Previous CDI	Urea (mg/dl)
Place of hospitalization	Creatinine (mg/dl)
Need for Intensive Care Unit (ICU)	Albumin (g/dl)
Origin	
Diarrhea classification	
Shock	
Death	

Countries	Studies
Argentina	Lopardo, G. et al, 2015 39
	OUR study
Brazil	Lopes Cançado, G. G. et al, 2018 92
Canada	Lowe, D. O. et al, 2006 93
	Dai, W. et al, 2020 94
Ob :	Li, Y. et al, 2016 95
China	Lv, Z. et al, 2014 96
	Tang, C. et al, 2018 97
	Zhou, F, F, et al, 2014 98
Colombia	Carvajal, C. et al, 2017 99 Salazar, C, L. et al, 2017 100
Denmark	Soes, L. M. et al, 2014 101
France	Le Monnier, A. et al, 2014
Hungary	Kurti, Z. et al, 2015 103
Iceland	Vesteinsdottir, I. et al, 2012 104
et	Ingle, M. et al, 2011 105
India	Ingle, M. et al, 2013 106
Japan	Mori, N. et al, 2015 107
Mexico	Morfin-Otero, R. et al, 2016 108
Poland	Czepiel, J. et al, 2014 109
Courth Africa	Legenza, L. et al, 2018 110
South Africa	Rajabally, N. et al, 2013 111
South Korea	Han, S. H. et al, 2014 112
Taiwan	Lee, Y. C. et al, 2012 113; Lin
Talwall	C. Y. et al, 2022 114
Thailand	Thipmontree, W. et al, 2011 115
Turkey	Ergen, E. K. et al, 2009 116
	Dial, S. et al, 2005 117
	Dial, S. et al, 2008 118
United Kingdom	Marwick, C. A. et al, 2013 119
	Suissa, D. et al, 2012 120
	Wilcox, M. H. et al, 2008 121
	Baxter, R. et al, 2008 122
	Haddad, F. G. et al, 2019 123
	Kuntz, J. L. et al, 2011 ¹²⁴ Kutty, P. K. et al, 2010 ¹²⁵
United States	Kwon, S. et al, 2017 126
	Naggie, S. et al, 2011 127
	Tabak, P. Y. et al, 2015 128
	Tartof, S. Y. et al, 2015 129

 $\textbf{Table 3.} \, \textbf{Summary of risk predictors from the meta-analysis} \, .$

RISK PREDICTOR	OR
Age	1,19 **
Biological sex	0,89 *
Prior ATB consumption	3,02 ***
Prior PPI consumption	1,29 ns
Prior hospitalization	2,45 ***
Prior CDI	1,76 ns
WBC (109 cel/mm ³)	1,35 *
Platelets (109 cel/ mm ³)	1,54 ns
Comorbidities	0)
Diabetes mellitus	1,26 ns
Heart disease	1,41 *
Kidney disease	2,23 ***
HIV	1,00 ns

Table 4. Meta-analysis dataset.

		CDI+	CDI-	TOTAL
No of individuals		11596	536467	548467
Sex	Male	44.33%	39.98%	40.06%
	Female	55.67%	60.02%	59.94%
Prior ATB consumption	With	39.95%	8.52%	9.11%
	Without	60.05%	91.48%	90.89%
Prior PPI consumption	With	29.87%	21.76%	22.18%
	Without	70.13%	78.24%	77.82%
Prior hospitalization	With	27.88%	16.80%	17.07%
	Without	72.12%	83.20%	82.93%